The potential of Beclin 1 as a therapeutic target for the treatment of breast cancer
- Authors
- Jung, Yoon Yang; Lee, Yu Kyung; Koo, Ja Seung
- Issue Date
- Feb-2016
- Publisher
- TAYLOR & FRANCIS LTD
- Keywords
- Autophagy; Beclin 1; Breast cancer; Targeted drug therapy
- Citation
- EXPERT OPINION ON THERAPEUTIC TARGETS, v.20, no.2, pp.167 - 178
- Indexed
- SCIE
SCOPUS
- Journal Title
- EXPERT OPINION ON THERAPEUTIC TARGETS
- Volume
- 20
- Number
- 2
- Start Page
- 167
- End Page
- 178
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/155104
- DOI
- 10.1517/14728222.2016.1085971
- ISSN
- 1472-8222
- Abstract
- Introduction: Beclin 1 plays a crucial role in autophagy via the Beclin 1 interactome, and is involved in various biological processes such as protein sorting, chemokinesis, and cell death. Via these biologic functions, Beclin 1 contributes to both tumor suppression and tumor progression.Areas covered: Beclin 1 plays a key biologic function on cell homeostasis and affects tumorigenesis. In this review, detailing up-to-date knowledge on the tumorigenic role of Beclin 1, its implication in breast cancer, and its utility as a breast cancer-specific drug target is discussed.Expert opinion: Because Beclin 1 is expressed in breast cancer cells, Beclin 1 could be a unique, effective drug target for the prevention and treatment of breast cancer. However, the expression of Beclin 1 varies according to cancer molecular subtypes, and Beclin 1 is involved in both breast cancer suppression and tumor progression; therefore, the decision of using a Beclin 1 inducer or inhibitor should be made based on breast cancer stage and subtype.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 교육협력지원교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/155104)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.